Amgen receives Scottish approval for multiple myeloma therapy Kyprolis

Amgen has received Scottish regulatory approval for a multiple myeloma treatment regimen incorporating its drug Kyprolis.

The Scottish Medicines Consortium has published advice accepting the use of Kyprolis in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

This takes into account the continuing availability of the patient access scheme agreed, or a list price that is equivalent or lower, and recognises the proven safety and efficacy of the therapy.

In clinical trials, patients treated with Kyprolis in combination with dexamethasone experienced a significant increase in progression-free survival compared to another dexamethasone-based regimen.

Kyprolis is the first and only proteasome inhibitor to demonstrate statistically significant improvements in overall survival rates in a head-to-head trial.

Tony Patrikios, executive medical director at Amgen in the UK and Ireland, said: "We know that time free of disease is precious and we are committed to advancing care for people with this difficult-to-treat blood cancer. We see carfilzomib as the backbone therapy for the management of relapsed multiple myeloma."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.